A non-invasive method to diagnose Alzheimer’s disease has shown promise in detecting the condition early on. The researchers developed a technology that can identify the pathological oligomeric forms of brain tau proteins in blood platelets of patients with Alzheimer’s disease and other neurodegenerative disorders. They uncovered that pathological forms of tau proteins correlate with decreased brain volume in areas of the brain that are known to be associated with the developments characteristic of Alzheimer’s. This finding takes us one step closer to using the so-called peripheral biomarkers for early diagnostic tests of Alzheimer’s disease.
This may come very handy for the development of more specific therapies as well as prevention tactics aimed at reducing the incidence rate of Alzheimer’s disease. Moreover, detecting tau proteins in blood platelets could help expand the understanding of the resulting neurodegeneration.